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Abstract
Coronavirus disease (COVID-19) initiates several life-threatening complications including coagulopathies with a unique char-
acteristic that made this problem challenging. Here we presented 4 cases of RT-PCR positive patients that have experienced 
deadly intraperitoneal hemorrhage with fourth WHO Bleeding Grade after overcoming their respiratory phase. COVID-19 
could induce several coagulopathies with different features that besides iatrogenic interventions increases its mortality and 
morbidity due to lack of clinical evidence based on well-designed randomized clinical trials on anticoagulation therapies 
(AT) and administration of varieties of newly approved and non-approved medicines. This report showed the urgent need for 
investigation on the pathophysiology of COVID-19-associated coagulopathy esp. in hemorrhagic events which are needed 
to make the best therapeutic decision.
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Highlights
• COVID-19-induced coagulopathies have a unique char-
acteristic, need their specific care.
• Internal bleeding has non-specific signs and symptoms 
making the early diagnosis difficult.
• Urgent need for research on the pathophysiology of these 
coagulopathies and clinical research on best choices, dos-
age, and duration of anticoagulant therapy is needed.
Background
Coronavirus disease (COVID-19) mortality and its associa-
tion with coagulopathies raised many questions about its 
pathogenesis. Similarities and differences of these coagula-
tion disturbances with other problems from disseminated 
intravascular coagulation to antiphospholipid syndrome 
(APS) and atypical hemolytic uremic syndrome (aHUS) 
show that COVID-19 coagulopathies have unique character-
istics [1]. Although anticoagulation therapies (AT) showed 
a reduction in mortality of disease this also increased major 
bleeding events in patients raising the question about the 
dosage and way of anticoagulation therapies [2]. There are 
few investigations about bleeding and its risk factors in 
COVID-19 but hyper fibrinolytic state, thrombocytopenia, 
coagulation consumption, hypoxia, cytokine storm, direct 
invasion of the virus, and AT are supposed to increase the 
incidence of bleedings. Although there are some reports 
about the occurrence of bleeding in COVID-19 from ICH 
and GI bleeding to focal kidney hemorrhage [3], this is the 
first case series of massive deadly intra-abdominal hemor-
rhage in COVID-19 patients.
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A 67-year-old woman with a history of several underlying 
diseases (Table 1) was admitted to the emergency depart-
ment with anorexia, Nausea, diarrhea, weakness, leth-
argy, nonproductive cough, and myalgia. In the physical 
exam, she had stable vital signs, fine crackle in the base 
of the lungs, and oxygen saturation of 81% on ambient 
air that was raised to 92% with a non-rebreather mask. 
Radiologic findings revealed bilateral infiltration of lungs 
with ground-glass opacity; she also had low GFR and a 
suspected case of acute renal failure (creatinine: 1.5 mg/
dl, GFR: 36 mL/min/1.73  m2).
Antiviral therapy with atazanavir–lopinavir, antibiotic 
therapy with azithromycin and ceftriaxone, famotidine, 
heparin, dexamethasone, and other conservative therapies 
had been started for her. The following days, dizziness 
besides decreases in oxygen saturation and diffuse course 
crackles of the lungs made us change her dexamethasone 
to methylprednisolone pulse, and add furosemide, Inter-
feron β1a, to her therapeutic regime, and start oxygen 
therapy with BiPAP and non-rebreather mask with an 
alternating schedule. She also had normal heart function 
and no signs of pulmonary embolism (PTE). During her 
hospitalization, although different methods were used for 
controlling her blood sugar (Bs), we were not successful 
in this job even by administering a high dose of insulin.
Six-day after hospitalization, he had an electrolyte 
imbalance that had been corrected and as we were short 
of atazanavir–lopinavir, we replaced it via lopinavir–rito-
navir. The patient’s clinical course was slowly improving 
to the 14th day of hospitalization but because of ‘slow’ 
improvements and possible nosocomial infection, the 
on-call physicians changed her therapeutic regime; furo-
semide and ceftriaxone had been stopped and piperacil-
lin–tazobactam, linezolid, montelukast, and seroflo spray 
had been started. Two days later heparin and lopina-
vir–ritonavir were replaced via enoxaparin and favipiravir; 
the next day, the patient’s clinical course changed a lot, her 
urine output was decreased and in the physical exam, she 
had a bulging abdomen with a decreased level of concise-
ness (Glasgow Coma Scale: 10) and 8 h later her cell blood 
count (CBC) showed a severe decrease in hemoglobin. She 
did not have hematuria, melena, rectorrhagia, hemoptysis, 
hematochezia, and even in stool exam, there was no occult 
blood. Her heart function was still normal due to port-
able echocardiography and in her peripheral blood smear 
(PBS) few hyper-segmented polymorphonuclear leukocyte 
(PMN) was seen with anisopoikilocytosis, hypochromic, 
polychromic, and microcytic RBCs with a decrease in 
platelet count and no schistocytes. She received 2 pack cell 
units, and in portable abdominal sonography, she had the 
echogenic area in her gall bladder and free fluid around the 
liver; these observations were approved with abdominal 
CT-Scan with contrast representing mild pleural effusion 
in both of her lungs, hemoperitoneum around her liver and 
spleen and retro hemoperitoneum in posterior renal space, 
left lateroconal fascia, in both of her psoas muscles with 
forwarding displacement of the left kidney (right ˂ left) 
extending to iliacus muscle (Fig. 1a).
After stabilizing the patient she was delivered to ICU. In 
there she received 2 more units of pack cells and the free 
fluid around the liver was tapped with a sonography guide 
which confirmed her internal bleeding. The next days she 
received 2 more pack cells and while it seems that decreases 
in hemoglobin were stopped she had been died due to car-
dio-pulmonary arrest.
Case 2
A 66-year-old woman was admitted due to her malaise and 
weakness. In physical exam and history taking she was a 
febrile woman (T = 38.2), stable in vital signs, and clear 
respiratory sounds complaining of constipation. After hos-
pitalization her viral pneumonia caused us to increase her 
corticosteroids on her 7th day of hospitalization and take 
care of her in ICU. Three days later she was discharged from 
ICU and her general condition was getting better, but 2 days 
later and after she had increased her physical activity by 
walking about 4 m, chest pain was referred to her right upper 
limb with a reduction in blood pressure caused us to limit 
his activities to complete bed rest, stop her thiazide drugs 
and rule out myocardial infarction and myocarditis; she also 
had problems in urination and abdominal pain mainly in her 
right lower quadrant that made us take a KUB X-ray from 
her representing no mechanical blockage in the GI system, 
presence of fecaloma in right and left colon and the bones 
with decreased density. On the morning of the next day, 
Cullen’s sign appeared in her umbilical region. Her pallor 
besides reduction in her blood pressure made her a criti-
cally ill patient; she also complained of a feeling of urinary 
urgency and pressure in her bladder while she was oliguria. 
In echocardiography, there was not any sign of cardiogenic 
shock and after a while, we noticed that she had a reduction 
in her hemoglobin from 11.2 to 9.6. In portable sonography, 
she had an 800  cm3 hypo echo area in her pelvic and 50  cm3 
in her abdominal wall. After stabilizing her with transfusion 
of pack cell and hydration we have taken her pelvic and 
abdominal CT-Scan with IV contrast (representing free fluid 
containing debris in favor of hemoperitoneum surrounding 
the liver and spleen. Large hematoma in the pelvic cavity 
(163 * 141 mm). Right, rectus muscle sheath hematoma (41 
* 68 mm) and right oblique and transversalis muscle sheath 
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hematoma) (Fig. 1b) and second sonography to observe the 
changes in the size of hematomas. She gets two more units 
of pack cell and 4 units of FFP and was transferred to the 
operation room due to increases in her hematoma detected 
with sonography.
In the operation room, the patient was packed before find-
ing her all bleeding site due to becoming unstable during the 
surgery and she did not take her consciousness after that. 
The next day, although her hemoglobin was corrected and 
she was stable, she had been become asystole and died.
Case 3
A 59-year-old man without a history of any specific disease 
was transferred from another site to our hospital due to the 
worsening of his condition. His symptoms had been started 
2 weeks before his transition and he was hospitalized in the 
referred site for 4 days. He had experience dyspnea, non-pro-
ductive coughs, chills, headaches, and pleuritic chest pain. In 
the emergency department enoxaparin, methylprednisolone, 
remdesivir, ciprofloxacin, cefepime, famotidine, and other 
treatments had been administered. In his CTA, the filling 
defects in 3 lobar arteries in the inferior right lobe and 2–3 
segmental arteries in the inferior lobes of both lungs repre-
senting PTE were observed. Then he had been transferred to 
ICU due to his condition and oxygen therapy with NIV and 
hemoperfusion (3 times) had been started for him. He had 
good clinical improvements and the dosage of his corticos-
teroid was reduced to 60 mg/day until the next 7 days. On his 
8th day of admission, warfarin was started for him. The next 
day he had been discharged from ICU and the other day the 
pains in his right lower limb made us consider DVT for him 
but there were not any signs of it in color Doppler sonogra-
phy. The amount of his urination was also reduced while in 
the physical exam it appears that his bladder was distended. 
His Foley catheter was changed and the suprapubic cath-
eter was tried which was not successful. 4 h later Cullen’s 
sign appeared in his suprapubic and periumbilical region 
and he had a reduction in his blood pressure with a sudden 
reduction in his hemoglobin from 12.3 to 6.7. In portable 
echocardiography, there was not any sign of left ventricular 
systolic. In portable sonography, free fluid in the abdomen 
and pelvic cavity (Table 1) was seen with an empty bladder. 
We have administered 4 units of FFP and then 30 mg prota-
mine sulfate but we could not stabilize his vital signs in the 
next 10 h even by vasopressors and transfusion and as result, 
he died while we couldn’t take an abdominal CT-Scan and 
send him to the operation room.
Case 4
An 80-year-old man with productive coughs, dyspnea, and 
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to the emergency department of Shohada hospital. He was an 
afebrile man with fine crackles in the base of his lungs and 
oxygen saturation of 70% in ambient air. His hypoxia caused 
us to use NIV and a non-rebreather mask in between for him. 
He had an incomplete right bundle branch block in ECG 
and pulmonary hypertension (PAP: 35–40 mmHg) in echo-
cardiography. Due to his acute renal failure, we performed 
sonography of the abdomen and kidney to roll out post-renal 
causes. In his sonography, there were several stones in his 
non-inflamed gallbladder and mild hydronephrosis that 
caused us to take an abdominal CT-Scan of him represent-
ing mild left lung pleural effusion which was not present 
before, left kidney hydronephrosis, gallstones, and a suspi-
cious stone in the distal third of left ureter near iliac vessels 
or vascular calcification there. His high level of D-dimer 
(1646) caused us to perform CTA of the lungs for him that 
there were not any signs of massive PTE in it. 15 days after 
his admission he had a sudden reduction in blood pressure, 
distended abdomen, pale skin. There were also decreases in 
the level of hemoglobin and DIC was also suspected (FDP: 
4, D-dimer: 942, fibrinogen: 186, Plt: 64,000, DIC score: 5). 
Although he got 4 units of pack cell and his heart function 
was normal according to the portable echocardiography, he 
had died in the morning of the next day.
Discussion and conclusions
Spontaneous intraperitoneal bleeding is a rare condition with 
different etiologies; clinical signs include sudden abdomi-
nal pain and distention, hypovolemic shock, and changing 
the color of the skin around the umbilicus and flank reign. 
The source of the bleeding could be varied from hepatic 
tumors to splenic, gastrointestinal, visceral artery abnormali-
ties and gynecologic conditions [4]. COVID-19-associated 
coagulopathies showed unique characteristics; during this 
infection, patients are at higher risk of developing arterial 
thrombosis and venous thromboembolism than those with 
sepsis-induced coagulopathy and DIC. Studies also showed 
a much lower occurrence of DIC in COVID-19 than sepsis 
patients, but besides this when the disease progresses from 
localized lung infection to its systemic phase, the character-
istics become more and more similar with DIC [1]. Although 
we did not check all fibrin markers in cases 2 and 3, the 
presented cases’ DIC scores were not suggestive for overt 
DIC (Table 1) [5] which accompanies unique coagulopathy 
features of COVID-19.
Hemophagocytic lymphohistiocytosis (HLH) could cause 
coagulation disorders leading to hemorrhage [6] and there is 
some evidence that hyper-inflammation state could induce 
HLH in COVID-19 patients [7], but clinical manifestation 
and laboratory markers (fever, splenomegaly, decreased 
counts in two cell lines, hypertriglyceridemia and/or hypofi-
brinogenemia, and hemophagocytosis) of our patients did 
not make this diagnosis as the H-score for our patient were 
less than 90. Catastrophic APS is a rare autoimmune dis-
ease that could cause coagulation disturbance by increas-
ing aPTT and there is some controversial evidence about 
its occurrence in critically ill patients with COVID-19 [8, 
9]; there are also two cases of COVID-19 bilateral adrenal 
hemorrhage that one of them had a history of antiphospho-
lipid syndrome and the other one had a suspected history of 
autoimmune diseases [10, 11], however, unfortunately, we 
did not check markers of this disease but none of our patients 
developed notable prolonged PTT.
Severe COVID-19 infections could also cause thrombotic 
microangiopathy (TMA) which is characterized by decreases 
in hemoglobin, increased lactate dehydrogenase (LDH), 
increased bilirubin, decreased haptoglobin, and appearance 
of schistocytes in peripheral blood smear [12]. TMA could 
also cause major bleeding events [13] and as the presented 
cases had only decreased in hemoglobin and increased LDH, 
this would not be the first choice underlying reason for their 
bleeding and even these changes could be iatrogenic due to 
several blood samplings.
The occurrence of VTE even in those receiving the 
full dose of anticoagulants and increased major bleed-
ing events in these patients showed the importance of 
Fig. 1  a Case 1 abdominal CT-
Scan with contrast representing 
hemoperitoneum around the 
liver, spleen (presented cut). 
b Case 2, abdominal CT-Scan 
with contrast representing in 
this cut large hematoma in the 
pelvic cavity (163 * 141 mm) 
and right rectus muscle sheath 
hematoma (41 * 68 mm)
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administration of an appropriate dose of anticoagulants, 
as high doses of them are not suitable for microangiopa-
thy too [2]. A retrospective study on 4389 hospitalized 
patients showed that AT has reduced mortality and intu-
bation rates in COVID-19 patients. In that study the rate 
of major bleeding in patients with a prophylactic dose of 
anticoagulant was approximately the same as those who 
did not get AT, these numbers were higher in patients who 
get a therapeutic dose of AT. All these data show a lack 
of high-quality evidence on the dosage of AT in COVID-
19 patients and well-conducted randomized clinical trials 
are needed [14]. High dose of anticoagulant in case 2 and 
4 due to high level of D-dimer and their clinical evalua-
tion seems to have harmed their prognosis, but there is 
also some evidence that reminds us hemorrhagic events 
in COVID-19 patients are more complicated to blame 
only AT; a study showed that GI bleedings in COVID-19 
patients were not associated with anticoagulant therapies 
and even prophylaxes with histamine receptor blockers 
or proton pump inhibitors did not decrease its prevalence 
which shows a non-acid mediated cause of bleeding in 
these patients [15]. This evidence shows that there are 
some other possible mechanisms for bleeding events; nev-
ertheless, a possible solution that is needed to be investi-
gated more is Nafamostat mesylate, an inhibitor of plas-
min, thrombin, and trypsin, that could be a choice for AT 
in high-risk patients as it does not have hemorrhagic side 
effects even at high doses [3].
New research that showed the potent role of remdesi-
vir to inhibit carboxylesterase-2 showed that iatrogenic 
interventions could cause some of these serious adverse 
effects [16]. Co-administration of antiviral drugs with oral 
anticoagulants in COVID-19 patients increases the plasma 
concentration of anticoagulants [3]; this could be the rea-
son for some hemorrhagic complications. Another exam-
ple is corticosteroids, these drugs could slightly increase 
the incidence of GI bleedings [17] and a study showed 
that chronic systemic corticosteroids increase the risk of 
major bleeding events and tamponade in those who under-
went aortic valve implantation [18]; besides this, several 
drug classes could also initiate drug-induced DIC [19] that 
their list is too long to be mentioned in this article and 
more studies are needed in this field as we use some newly 
administered drugs in COVID-19 and this might be the 
adverse effect of them.
Finally, this case series besides other intraperitoneal 
bleeding reports in COVID-19 patients [10, 11, 20, 21] dem-
onstrated that COVID-19 coagulopathy and AT should be 
studied more. To reduce the disease mortality and morbid-
ity investigations on the pathophysiology of COVID-19-as-
sociated coagulopathy and finding the best intervention to 
prevent or treat it is needed.
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